MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Diabetes Treatment and Management
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,896 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,896 works in the cohort · of 4,299,418page 31 of 78

Labels cover 11 of 3,896 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,896 of 3,896 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundunlabeled
Cardiorenal Protection in Diabetic Kidney Disease
Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney
2021· review· en· Endocrinology and Metabolism· Medicine
machine prediction:candidate · noneconsensus · none
19
citations
affunlabeled
Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
Thomas M. Caparrotta, Luke A. K. Blackbourn, Stuart J. McGurnaghan, John Chalmers, Robert S. Lindsay, Rory J. McCrimmon +8 more
2020· article· en· Diabetes Care· Medicine
machine prediction:candidate · noneconsensus · none
19
citations
afffundno abstractunlabeled
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Melanie J. Davies, Peter van der Meer, Subodh Verma, Shachi Patel, Khaja Chinnakondepalli, Barry A Borlaug +10 more
2025· article· en· The Lancet Diabetes & Endocrinology· Medicine
machine prediction:candidate · noneconsensus · none
19
citations
afffundno abstractunlabeled
Cardiovascular biology of the GIP receptor
Amanda A. Greenwell, Jadin J. Chahade, John R. Ussher
2019· review· en· Peptides· Medicine
machine prediction:candidate · noneconsensus · none
19
citations
afffundunlabeled
A Beautiful Cell (or Two or Three?)
Patricia L. Brubaker
2012· letter· en· Endocrinology· Medicine
machine prediction:candidate · noneconsensus · none
19
citations

How this was built: Screen · Findings · About